Amphiphilic peptides and hydrogel matrices thereof for bone repair
The present invention relates in general to the field of tissue engineering and more specifically to amphiphilic peptides and peptide matrices thereof useful in vitro and in situ biomineralization and inducing bone repair. The present invention provides peptides, which are useful in hydrogels and other pharmaceutical compositions, and methods and kits of use for bone repair and promotion of biomineralization. Certain hydrogels according to the invention comprise cells within or adhered to the peptide matrix.
1. An amphiphilic peptide comprising the amino acid sequence Asp-(Phe-Asp) 5 ; and
wherein the peptide is selected from the group consisting of:
Pro-Asp-(Phe-Asp) 5 -Pro (SEQ ID NO:22); and
Ac-Pro-Asp-(Phe-Asp) 5 -Pro-NH 2 (SEQ ID NO:19).
2. The amphiphilic peptide of claim 1 wherein the amino terminus is acetylated.
3. The amphiphilic peptide of claim 1 wherein the carboxy terminus is amidated.
4. The amphiphilic peptide of claim 1 , wherein the peptide is Ac-Pro-Asp-(Phe-Asp) 5 -Pro-NH 2 (SEQ ID NO:19).
5. The amphiphilic peptide of claim 1 , wherein the peptide is Pro-Asp-(Phe-Asp) 5 -Pro (SEQ ID NO: 22).
6. A pharmaceutical composition comprising at least one amphiphilic peptide according to claim 1 in the form of a hydrogel composition and optionally comprising one or more of a pre-loaded mineral-salt solution or aggregate or a pre-loaded polysaccharide.
7. The pharmaceutical composition of claim 6 , wherein the peptide is Ac-Pro-Asp-(Phe-Asp) 5 -Pro-NH 2 (SEQ ID NO:19).
8. The pharmaceutical composition of claim 6 , wherein the peptide is Pro-Asp-(Phe-Asp) 5 -Pro (SEQ ID NO: 22).
9. A hydrated pharmaceutical composition comprising at least one amphiphilic peptide having a sequence selected from the group consisting of:
(SEQ ID NO: 22)
Pro-Asp-Phe-Asp-Phe-Asp-Phe-Asp-Phe-Asp-Phe-Asp-
Pro;
(SEQ ID NO: 56)
Pro-Asp-Phe-Asp-Phe-Asp-Phe-Asp;
(SEQ ID NO: 57)
Pro-Asp-Phe-Asp-Phe-Asp-Phe-Asp-Phe-Asp;
(SEQ ID NO: 58)
Pro-Asp-Phe-Asp-Phe-Asp-Phe-Asp-Phe-Asp-Phe-Asp;
(SEQ ID NO: 59)
Pro-Asp-Phe-Asp-Phe-Asp-Phe-Asp-Phe-Asp-Phe-Asp-
Phe-Asp;
(SEQ ID NO: 60)
Pro-Asp-Phe-Asp-Phe-Asp-Phe-Asp-Phe-Asp-Phe-Asp-
Phe-Asp-Phe-Asp;
(SEQ ID NO: 61)
Asp-Phe-Asp-Phe-Asp-Phe-Asp-Pro;
(SEQ ID NO: 62)
Asp-Phe-Asp-Phe-Asp-Phe-Asp-Phe-Asp-Pro;
(SEQ ID NO: 63)
Asp-Phe-Asp-Phe-Asp-Phe-Asp-Phe-Asp-Phe-Asp-Pro;
(SEQ ID NO: 64)
Asp-Phe-Asp-Phe-Asp-Phe-Asp-Phe-Asp-Phe-Asp-Phe-
Asp-Pro;
(SEQ ID NO: 65)
Asp-Phe-Asp-Phe-Asp-Phe-Asp-Phe-Asp-Phe-Asp-Phe-
Asp-Phe-Asp-Pro;
(SEQ ID NO: 66)
Pro-Asp-Phe-Asp-Phe-Asp-Phe-Asp-Pro;
(SEQ ID NO: 67)
Pro-Asp-Phe-Asp-Phe-Asp-Phe-Asp-Phe-Asp-Pro;
(SEQ ID NO: 68)
Pro-Asp-Phe-Asp-Phe-Asp-Phe-Asp-Phe-Asp-Phe-Asp-
Phe-Asp-Pro;
(SEQ ID NO: 69)
Pro-Asp-Phe-Asp-Phe-Asp-Phe-Asp-Phe-Asp-Phe-Asp-
Phe-Asp-Phe-Asp-Pro.
10. The hydrated pharmaceutical composition of claim 9 , wherein said composition is a hydrogel composition.
11. The hydrated pharmaceutical composition of claim 9 , further comprising one or more of a pre-loaded mineral-salt solution or aggregate or a pre-loaded polysaccharide.
12. The hydrated pharmaceutical composition of claim 11 , wherein said pre-loaded mineral salt is a calcium phosphate mineral selected from the group consisting of: amorphous calcium phosphate, tricalcium phosphate and hydroxyapatite or the pre-loaded polysaccharide is selected from the group consisting of: hyaluronic acid, alginate and sulfated polysaccharide.
13. The hydrated pharmaceutical composition of claim 9 , further comprising at least one therapeutic agent.
14. The hydrated pharmaceutical composition of claim 13 , wherein said therapeutic agent is selected from the group consisting of: active proteins, growth factors, cytokines, chemotherapeutic drugs, enzymes, anti-microbials, anti-resorptive agents and anti-inflammatory agents.
15. An implant comprising a pharmaceutical composition according to claim 9 and optionally further comprising a metal structure.
16. A kit comprising at least one amphiphlic peptide according to claim 1 and optionally further comprising a pharmaceutically acceptable carrier or excipient and an optional means for delivery of the peptide or peptide and carrier or excipient.
17. A method for the treatment of progression of osteoporosis or pre-osteoporotic condition, said method comprising administering to a subject in need thereof a therapeutically effective amount of a hydrated pharmaceutical composition according to claim 9 .
18. A method for the treatment of progression of osteoporosis or pre-osteoporotic condition, said method comprising administering to a subject in need thereof an implant according to claim 15 .